靶向PD-1/PD-L1的结直肠癌免疫治疗研究进展  

Recent Advancesin Colorectal Cancer Therapy Targeting PD-1/PD-L1

作　　者：刘航 丁杰 吴明[3] 李显[1,2] 张林 曾家兴 LIU Hang;DING Jie;WU Ming;LI Xian;ZHANG Lin;ZENG Jiaxing(ZunYi Medical Univercity,Zunyi,Guizhou,563003,China;Department of Gastroenterology,Guizhou People’s Hospital,Guiyang,550002,China;Department of Emergency Internal Medicine,Guizhou People’s Hospital,Guiyang,550002,China)

机构地区：[1]遵义医科大学,贵州省遵义市563003 [2]贵州省人民医院胃肠外科,贵阳市550002 [3]贵州省人民医院急诊内科,贵阳市550002

出　　处：《医学分子生物学杂志》2020年第2期157-163,共7页Journal of Medical Molecular Biology

基　　金：国家自然科学基金(No.81360366、81302169);贵州省社会发展攻关项目(No.黔科合SY字[2014]3023号);贵州省优秀青年科技人才培养对象(No.黔科合平台人才[2017]5602号);贵州省高层次创新型人才培养对象(No.GZSYQCC[2014]001号);贵州省高层次留学人才创新创业项目(No.[2018]04号);贵州省科技计划项目(No.黔科合基础[2019]1198号)。

摘　　要：传统的外科手术方式、治疗理念在不断改进,但对于改善结直肠癌患者的预后鲜有重大的突破。近年来,靶向程序性细胞凋亡蛋白-1(programmed death-1 receptor,PD-1)/程序性细胞凋亡蛋白配体-1(programmed cell death protein ligand-1,PD-L1)在部分晚期结直肠癌患者的治疗中效果显著,其抑制剂Pembrolizumab和Nivolumab被美国食品药品管理局(US Food and Drug Administration,FDA)批准用于转移性高度微卫星不稳定型或错配修复缺陷型(dMMR/MSI-H)实体瘤的末线治疗。文章综述了近年来靶向PD-1/PD-L1的结直肠癌免疫治疗研究进展。Traditional surgical procedures and concepts are continuously modified.However,few significant breakthroughs have been made in improving the prognosis of patients suffering from colorectal cancer.In recent years,researches focusing on Programmed death-1 receptor(PD-1)and its ligand Programmed cell death protein ligand-1(PD-L1),have achieved encouraging results in ameliorating the symptoms of advanced colorectal cancer.Pembrolizumab and Nivolumab,the in-hibitors of PD-1 has been approved by the US Food and Drug Administration(FDA)for end-line treatment of dMMR/MSI-H phenotype solid tumors.This article reviews the recent advances in the research of PD-1/PD-L1 and its inhibitors in the treatment of colorectal carcinoma.

关 键 词：靶向程序性细胞凋亡蛋白-1/程序性细胞凋亡蛋白配体-1 结直肠癌 免疫治疗 抑制剂 

分 类 号：R735.3[医药卫生—肿瘤]